恒瑞医药：海曲泊帕乙醇胺片新适应症上市许可申请获受理

Core Viewpoint - Jiangsu Hengrui Medicine has received the acceptance notice from the National Medical Products Administration for its drug application of Hecuqipar Ethanolamine Tablets, targeting the treatment of persistent and chronic primary immune thrombocytopenia (ITP) in adults and children aged 6 and above [1] Group 1: Product Development - The drug has already been approved for two adult indications [1] - The Phase III clinical trial is expected to reach its primary endpoint by March 2025 [1] - The total research and development investment for this drug has reached approximately 44.587 million yuan [1] Group 2: Market Potential - ITP is a common bleeding disorder in children and adolescents, indicating a strong clinical treatment demand [1] - Similar products are already available in foreign markets, with an estimated global sales of approximately 2.59 billion dollars in 2024 [1]